1. Home
  2. News & Publications
  3. Research News

Jan. 15, 2015 Press Release Biology Medicine / Disease

Alzheimer's plaques reduced by targeting sugar attachment to the BACE1 enzyme

Researchers at the RIKEN-Max Planck Joint Research Center in Japan have demonstrated that hallmark symptoms of Alzheimer’s disease can be reduced when sugars are prevented from binding to one of the key enzymes implicated in the disease. The new findings, reported in EMBO Molecular Medicine, show that abnormal attachment of a particular sugar to the enzyme BACE1 is a critical factor leading to the formation of Aβ plaques in the brain, and that plaques were reduced and cognitive performance improved when this action was prevented in mice through loss of the enzyme GnT-III. In doing so, this work has revealed a novel mechanism for Alzheimer’s disease development, potentially opening the way to a new approach for treatment.

A major factor contributing to Alzheimer’s disease is the formation of pathogenic Aβ plaques in the brain when the molecule APP is abnormally cut by the enzyme BACE1, producing Aβ. Because of this, developing drugs that prevent BACE1 from cleaving APP is a central focus of Alzheimer’s research. A major stumbling block in these efforts however, is finding a way to do this without disturbing vital processes in the brain and body that are regulated by normal BACE1 activity.

Through a series of experiments, researchers led by Yasuhiko Kizuka, Shinobu Kitazume, and Naoyuki Taniguchi at RIKEN, in collaboration with Tamao Endo and Shigeo Murayama at the Tokyo Metropolitan Institute of Gerontology, showed that much of the BACE1 found in the brains of Alzheimer’s disease patients is modified by the attachment of a particular sugar with the help of the enzyme GnT-III. Hypothesizing that preventing this process would relieve Alzheimer’s symptoms, the researchers crossed mice that lacked GnT-III with others that express human APP in the brain. They found that Aβ levels and plaque formation were reduced in these hybrid mice, and that cognitive performance was better. 

Next, they showed that eliminating the sugared versions of BACE1 is effective in preventing plaque formation because BACE1 without the sugar is destroyed and cannot interact with APP. Using a difficult procedure called subcellular fractionation, they determined that sugared BACE1 is located near APP within cells. However, if the sugar is not attached to it, it is found further from APP and closer to lysosomes—subcellular structures that degrade unneeded molecules. When they examined the mice that lacked GnT-III, they indeed found lower amounts of BACE1.

They then showed that this approach is highly selective. BACE1 normally cleaves several proteins other than APP, and while mice lacking BACE1 also lack Aβ plaques, they also suffer from many side effects and often do not live longer than 4 weeks. On the other hand, the mice tested by Kizuka and his colleagues are healthy, fertile, and behave normally. When examined, these mice did not exhibit higher levels of other proteins that are normally cleaved by BACE1, showing that targeting GnT-III likely only prevents BACE1 from cleaving APP, and can act to reduce Alzheimer’s pathology with potentially few side effects.

This research highlights the importance of glycosylation—the modification of proteins by sugars. Far from being rare, it is the most common way in which protein structure is altered, with more than half of proteins being glycosylated in mammals. Kizuka is excited that perhaps now this process will get the attention and press it deserves. He notes that, “although a sugar change is often considered just a marker for disease or a specific cell type, our team has clearly demonstrated the functional role of a glycan during AD development.” He added that, “this work offers a good opportunity for many AD researchers to reconsider the importance of glycosylation.”

While knocking out GnT-III is feasible in mice, a drug that inhibits GnT-III in the brain has the potential to be an effective treatment for reducing Aβ plaque formation and cognitive decline in humans. Towards this end, Kizuka and colleagues are using a novel screening procedure in collaboration with the RIKEN Program for Drug discovery and Medical Technology Platforms to search for GnT-III inhibitors.

Reference

  • Yasuhiko Kizuka, Shinobu Kitazume, Reiko Fujinawa, Takashi Saito, Nobuhisa Iwata, Takaomi C. Saido, Miyako Nakano,Yoshiki Yamaguchi, Yasuhiro Hashimoto, Matthias Staufenbiel, Hiroyuki Hatsuta, Shigeo Murayama, Hiroshi Manya, Tamao Endo, Naoyuki Taniguchi, "An aberrant sugar modification of BACE1 blocks its lysosomal targeting in Alzheimer’s disease", EMBO Molecular Medicine, doi:10.15252/emmm.201404438

Contact

Team Leader
Naoyuki Taniguchi
Disease Glycomics Team
Systems Glycobiology Research Group
RIKEN-Max Planck Joint Research Center for Systems Chemical Biology
Global Research Cluster

Adam Phillips, PhD
RIKEN Global Relations and Research Coordination Office
Tel: +81-(0)48-462-1225 / Fax: +81-(0)48-463-3687
Email: pr@riken.jp

Immunostaining of Aβ plaques

Immunostaining of Aβ plaques showed that while the normal mouse model for Alzheimer’s disease displayed numerous Aβ plaques (left, black arrows), the number of plaques was significantly reduced when these mice lacked GnT-III (right). Scale bar, 300 μm

Immunostaining of mouse brain showing locatization of BACE1 and APP

Immunostaining of 12-month-old mouse brain showed that BACE1 and APP were co-localized (yellow cells, right column) less often in the mouse model for Alzheimer’s disease when the mice lacked GnT-III

Top